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Low Sensitivity of BinaxNOW RSV in Infants
Roy P. Zuurbier,1,2 Louis J. Bont,1 Annefleur C. Langedijk,1 Mirjam Hamer,1 Koos Korsten,1 Simon B. Drysdale,3 Matthew D. Snape,3 Hannah Robinson,3 
Andrew J. Pollard,3 Federico Martinón-Torres,4,5 Carmen Rodríguez-Tenreiro Sánchez,4 Alberto Gómez-Carballa,4,5 Ana Isabel Dacosta-Urbieta,4,5  
Terho Heikkinen,6 Steve Cunningham,7 Marlies A. van Houten,2 and Joanne G. Wildenbeest1; for the RESCEU Investigators
1Department of Paediatric Immunology and Infectious Diseases, Wilhelmina Children’s Hospital/University Medical Center Utrecht, Utrecht, Netherlands, 2Spaarne Gasthuis Academy, Hoofddorp 
and Haarlem, Hoofddorp, Netherlands, 3Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom, 
4Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 5Genetics, Vaccines and 
Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Spain, 6Department of Pediatrics, University of Turku and Turku University Hospital, 
Turku, Finland, 7Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom
Background. Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can op-
timize clinical management and minimize use of antibiotics. BinaxNOW RSV (BN) is a rapid antigen detection test that is widely 
used. We aimed to validate the sensitivity of BN in hospitalized and nonhospitalized infants against the gold standard of molecular 
diagnosis.
Methods. We evaluated the performance of BN in infants with acute respiratory tract infections with different degrees of disease 
severity. Diagnostic accuracy of BN test results were compared with molecular diagnosis as reference standard.
Results. One hundred sixty-two respiratory samples from 148 children from October 2017 to February 2019 were studied. 
Sixty-six (40.7%) samples tested positive for RSV (30 hospitalizations, 31 medically attended episodes not requiring hospitalization, 
and 5 nonmedically attended episodes). Five of these samples tested positive with BN, leading to an overall sensitivity of BN of 7.6% 
(95% confidence interval [CI], 3.3%–16.5%) and a specificity of 100% (95% CI, 96.2%–100%). Sensitivity was low in all subgroups.
Conclusions. We found a low sensitivity of BN for point-of-care detection of RSV infection. BinaxNOW RSV should be used 
and interpreted with caution.
Keywords.  antigen detection; birth cohort; diagnosis; point-of-care test; respiratory syncytial virus.
Respiratory syncytial virus (RSV) is the most common path-
ogen identified in young children with acute lower respiratory 
tract infections [1]. Respiratory syncytial virus is a major cause 
of hospital admissions with an estimated hospitalization rate of 
19 per 1000 children under the age of 1 year worldwide [2–4].
Reliable rapid diagnostic tests are needed to improve patient 
management regarding unnecessary use of antibiotics [5, 6] and 
to enable cohorting of hospitalized children in the RSV season. 
An evolving role for rapid tests is as a companion diagnostic for 
the development of novel RSV antivirals and evaluation of effi-
cacy of new RSV vaccines, for which it will be important to have 
both a reliable and rapid RSV test.
The current gold standard for RSV diagnosis is laboratory-
based reverse-transcriptase polymerase chain reaction 
(RT-PCR). This technique is highly sensitive and specific, 
but it is time-consuming, relies on trained laboratory staff, 
and typically has a long lag time to provide results to clin-
ical teams (24–48 hours), negating its clinical value. Although 
in recent years point-of-care tests (POCTs) utilizing molec-
ular methods have been developed, they remain expensive 
and consequently are not widely adopted in clinical prac-
tice. A range of alternative POCTs are available and used in 
clinical practice that are fast, easy to use by nonlaboratory 
personnel, and often less expensive compared with routine 
RT-PCR. The turnaround time of most POCTs is less than 1 
hour. Respiratory syncytial virus rapid antigen detection tests 
(RADTs) are POCTs with high specificity, but a wide range in 
sensitivity, partially depending on viral load [7, 8]. Two re-
cent meta-analyses showed a pooled sensitivity of 81% (95% 
confidence interval [CI], 78%–84%) [9] and 75.9% (95% CI, 
73.1%–78.5%) for RSV RADTs in general in children com-
pared with RT-PCR [10]. There is large heterogeneity in these 
studies, which are often sponsored by the tests’ manufacturer. 
In addition, many studies are performed retrospectively and 
in hospitalized children, whereas diagnostics are not evalu-
ated at point of care (POC). As a result, sensitivity of indi-
vidual studies vary considerably from 41.2% [11] to 83% [12].
The aim of the current study was to evaluate for the first time 
the performance of the RADT BinaxNOW RSV ([BN] Alere 
Inc., Waltham, MA) [13] to diagnose RSV infection in infants 
with acute respiratory tract infection (ARTI) in different clin-
ical settings in a large international prospective clinical study.
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METHODS
Study Population
The study population consisted of infants (<1 year old) with 
an ARTI who were participating in the REspiratory Syncytial 
virus Consortium in EUrope (RESCEU) [14] birth cohort 
study or the case-control study during 2 RSV seasons be-
tween 1 October 2017 and 28 February 2019. The RESCEU is 
a European Union-funded consortium study aiming to define 
RSV burden of disease in Europe. The current study was per-
formed in the Netherlands, Spain and the United Kingdom. 
The birth cohort study consists of healthy infants prospective 
followed up from birth. In their first year of life, during the 
RSV season(s), a RSV test was performed each time they ex-
perienced any symptoms of an ARTI. Infants were tested by 
a trained member of the study team at home or at the clinic 
and could be tested during more than 1 separate episode. The 
case-control study is a cross-sectional study performed in in-
fants admitted to hospital, attending emergency departments 
(ED) or general practitioners (GPs) with symptoms of ARTI. 
Details of the study design and procedures can be found at 
clinicaltrials.gov (NCT03627572, NCT03756766). Informed 
consent was obtained from the parents of all study parti-
cipants. All children with ARTI were eligible for RSV POC 
testing. For practical reasons, not all children could be tested 
with both the BN and the reference test. For this analysis, we 
included only samples on which both BN and a molecular ref-
erence test were performed (Figure 1).
Data on age, sex, comorbidities, duration of symptoms of 
ARTI, and level of medical care needed (hospitalized, medically 
attended [MA] ARTI, and non-MA ARTI) were obtained by 
completing questionnaires and case report forms. We defined 
3 levels of medical care: (1) infants with ARTI who were hospi-
talized (including a subgroup of infants who were admitted to 
the pediatric intensive care unit [PICU]); (2) infants with MA 
ARTI, defined as infants who were seen at the ED or GP but 
were not admitted to the hospital; and (3) infants with non-MA 
ARTIs who did not see any doctor during the entire ARTI ep-
isode. In addition, the ReSViNET score was used to determine 
disease severity (Supplementary Table 1) [15].
Study Procedures
A nasal flocked swab (FLOQSwab; Copan Diagnostics) was 
collected by a trained member of the study team and directly 
stored in one of the following viral transport media: MicroTest 
M4RT (3 mL; Remel) or UTM (3 mL; Copan Diagnostics). 
A  maximum of 400  μL of the viral transport medium was 
used for POC testing. Samples were transported at room tem-
perature. The BN test was performed within 4 hours. The re-
maining sample was stored in aliquots at −80°C or discarded 
if RSV was negative (infant case-control study). The molecular 
reference test was either Xpert Xpress Flu/RSV assay (Cepheid, 
Sunnyvale, CA) [16] or Alere i RSV assay (Alere Inc., Waltham, 
MA) [17] depending on availability of the tests at participating 
sites. The staff had hands-on training on how to sample patients 
and how to use the available POC tests before the start of the 
studies.
All tests were performed according to the manufacturer’s in-
struction. In short, for the BN assay, 100 μL of the viral trans-
port medium mixed with the swab was aspirated with the 
included transfer pipette. The BN card was opened, and the en-
tire content of the filled pipette was slowly expelled onto the 
sample pad of the device. A timer was set at 15 minutes to avoid 
inaccurate test results. After these 15 minutes, test results were 
read immediately from the BN test card, by visual inspection 
(Supplementary Text).
Statistical Analysis
A positive molecular test for RSV was defined as the reference 
outcome. The BN results were compared with the reference test 
to measure diagnostic accuracy. Dichotomous variables were 
compared using χ 2 or Fisher’s exact test as appropriate. P < .05 
were considered statistically significant. Univariate logistic re-
gression analysis was used to determine whether false-negative 
BN tests results were associated with age, duration of symp-
toms, or ReSViNET score. Statistical analyses were conducted 
using IBM SPSS Statistics for Windows, version 25.0 (IBM 
Corp., Armonk, NY).
RESULTS
In total, 162 nasal swabs from 148 infants with symptoms of 
ARTI were tested with BN and the reference test. One hundred 
thirty-four infants were tested once and 14 infants were tested 
twice during 2 separate ARTI episodes. Of the 162 samples, 36 
(22.2%) were from hospitalized infants, 83 (51.2%) from in-
fants who had an MA ARTI, 41 (25.3%) from infants who had 
a non-MA ARTI, and 2 samples were from infants with missing 
data about level of care. Baseline characteristics are summarized 
in Table 1. Median age at moment of ARTI was 84 days (inter-
quartile range, 39–178 days). Ninety-eight (78.4%) of the swabs 
were taken within 5 days after the start of symptoms. Four in-
fants had comorbidities, including the following: prematurity, 
cardiomyopathy, and congenital bronchomalacia.
There were 66 RSV infections detected in 162 nasal swabs 
(40.7%), 5 (7.6%) of which tested positive by BN (Figure  1). 
All BN-positive samples also tested positive by the reference 
test. One infant had 2 RSV-positive episodes (1 episode of 
which was BN positive). Test characteristics of BN are shown 
in Table 2. Sensitivity was not significantly related to age, du-
ration of symptoms, disease severity, or level of care required 
(Table 3). Sensitivity was higher in the subgroup of infants ad-
mitted to a PICU compared with other infants (22.2% versus 
5.3%), although this difference was not statistically significant 
(P = .134). Univariate logistic regression analysis confirmed 
low sensitivity of BN in all subgroups.
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Test Procedure
Because sensitivity of BN was lower than previously pub-
lished, we carefully analyzed our procedures. Uniform 
standard operating procedures regarding sample collection 
and POC testing with BN was written and distributed to 
all participating centers before the start of the study. In the 
course of the study, BN test procedure was thoroughly evalu-
ated, including a careful analysis by employees from the man-
ufacturer (Supplementary Text). No technical explanation 
was found for the low sensitivity of BN.
DISCUSSION
In this study, we have shown that the overall sensitivity of BN 
was only 7.6% (95% CI, 3.3%–16.5%) in infants with ARTIs of 
varying clinical severity (hospitalized, MA ARTI, and non-MA 
ARTI). Highest sensitivity was seen in infants admitted to the 
PICU, although this was still only 22%. The sensitivity of BN in 
the current study is remarkably lower than previously reported. 
Two recent meta-analyses showed a pooled sensitivity of BN of 
81% (95% CI, 74%–87%) [9] and 72.2% (95% CI, 65.2%–79.1%) 
[10], respectively. Individual studies showed a sensitivity varying 
from 41.2% to 83% in children when compared with RT-PCR 
[7, 11, 12, 18–21]. Characteristics of these studies are shown 
in Table  4. The sample size of the studies varied between 66 
and 720 participants with various age limitations. The 4 larger 
studies were all performed in children under the age of 3 years 
with nasopharyngeal aspirate (NPA) or nasal wash (NW) and 
showed a sensitivity of 63%–83% compared with RT-PCR. The 
3 other studies were smaller and mainly used nasopharyngeal 
swab (NPS) as sampling method. The sensitivity of these studies 
varied between 41% and 80% compared with RT-PCR. The 
sample size of our study was 162, which is comparable but still 
smaller than the 4 larger studies. The low sensitivity in our study 
compared with the other studies is striking and necessitated a 
thorough analysis of the differences with the other studies and 
other possible explanations for the low sensitivity observed in 
our study. One of the differences between our study and the 
other studies is that we also included infants with non-MA 
ARTI, whereas other studies evaluated the performance of BN 
mainly in hospitalized children.
We reflected on possible explanations for the low sensitivity 
observed in our study. We considered that reduced disease se-
verity could be linked to lower viral loads in infants recruited 
[22] and subsequently a lower sensitivity. However, even in the 
group of infants with severe disease who were admitted to hos-
pital, sensitivity was less than 10%. Other factors that might in-
fluence sensitivity are age and duration of symptoms because 
both are probably related to viral load. False-negative results are 
more often seen with an increasing age [20] or longer duration 
of symptoms [7, 20, 21, 23]. However, all children in our study 
were younger than 1 year of age, and the majority (78.4%) were 
tested within 5 days after the start of symptoms, thus this could 
not explain the low sensitivity.
We also considered sampling methods as a cause of the low 
sensitivity in our study. Compared with the other published 
studies, we used nasal flocked swabs in 3 mL UTM or M4RT 
instead of NPS in 1 or 1.5 mL viral transport medium or NW/
ARTI episodes
n = 269
Samples 
tested with both BN and 
reference test
n = 162
BN
positive
n = 5
Reference test
positive
n = 5
“true positive”
Reference test
negative
n = 0
“false positive”
BN
negative
n = 157
Reference test
positive
n = 61
“false negative”
Reference test
negative
n = 96
“true negative”
Figure 1. Study flow chart showing eligible acute respiratory tract infection (ARTI) episodes and test results of samples that were tested by BinaxNOW RSV (BN) and the 
reference test. n, number of ARTI episodes.
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NPA. We have previously shown that nasal aspirates are asso-
ciated with higher sensitivity than nonflocked swabs to detect 
RSV by PCR [24]. Other studies have shown that sensitivity was 
comparable between NW or NPA and NPS with flocked swabs 
for detection of viruses by PCR [25, 26]. In addition, Blaschke 
et al [27] showed that midturbinate (nasal) flocked swabs are 
comparable to NPS for quantitative detection of RSV in in-
fants, showing similar viral loads. Although no studies have 
previously compared the performance of rapid antigen testing 
in nasal swabs compared with aspirates or washes, we do not 
think that sampling methods fully explain the low sensitivity of 
BN. Temporal evolution of the binding site of the RSV fusion 
protein may have changed over time with loss of binding to the 
BN antibody, ultimately resulting in decreased sensitivity. We 
have limited information on viral sequences in our patient pop-
ulation. Because most of the known antigenic sites of the RSV 
fusion protein are generally well conserved, we believe this ex-
planation for the low sensitivity of BN is unlikely [28]. Taken 
together, we have not found a methodological or biological ex-
planation for the low sensitivity of BN in our study compared 
with previous reports.
A strength of our study is that it is part of a large prospec-
tive clinical study with a well defined study population per-
formed in different centers across Europe. Our study is based 
Table 1. Characteristics of Infants at Moment of ARTI Episode
Reference Testa RSV Positive RSV Negative
 
Total ARTI Episodes 
n = 162
BinaxNOW Positive 
(TP)  
n = 5
BinaxNOW  
Negative  
(FN)  
n = 61
BinaxNOW  
Negative  
(TN)  
n = 96
Age at moment of ARTI episode, days (median [IQR]) 84 [39–178] 42 [33–203] 99 [49–197] 67 [34–161]
Sex, male (n, %)b 94 (58.0%) 4 (80.0%) 33 (54.1%) 57 (59.4%)
Comorbidity (n, %)c 4 (2.5%) 1 (20.0%) 3 (4.9%) 0 (0%)
Duration of symptomsd  
days (median [IQR])
3 [2–5] 4 [2–5] 3 [2–4] 3 [2–6]
Level of Care Needed (n, %)e
 Non-MA ARTI 41 (25.3%) 0 (0.0%) 5 (8.2%) 36 (37.5%)
 MA ARTI 83 (51.2%) 3 (60.0%) 28 (45.9%) 52 (54.2%)
 Hospitalized 36 (22.2%) 2 (40.0%) 28 (45.9%) 6 (6.3%)
 PICU 11 (30.6%) 2 (100%) 7 (25.0%) 2 (33.3%)
Country (n, %)
 Netherlands 118 (72.8%) 3 (60.0%) 53 (86.9%) 62 (64.6%)
 United Kingdom 14 (8.6%) 0 (0.0%) 0 (0.0%) 14 (14.9%)
 Spain 30 (18.5%) 2 (40.0%) 8 (13.1%) 20 (20.8%)
ReSViNET scoref  
(median [IQR])
3 [1–6] 6 [5–16] 5 [3–9] 1 [1–3]
Reference Test (n, %)
 Alere i RSV 120 (74.1%) 5 (100.0%) 32 (52.5%) 83 (86.5%)
 Xpert Xpress 42 (25.9%) 0 (0.0%) 29 (47.5%) 13 (13.5%)
 Flu/RSV     
Abbreviations: ARTI, acute respiratory tract infection; FN, false negative; IQR, interquartile range; MA ARTI, medically attended ARTI; n, number of ARTI episodes; PICU, pediatric intensive 
care unit; RSV, respiratory syncytial virus; TN, true negative; TP, true positive.
NOTE: Categorical data are expressed as frequency (%), and continuous data are expressed as median [IQR]. Percentages may not equal 100, because of rounding and missing values. P 
values were not determined because of the low number of positive test results with BinaxNOW RSV.
aAlere i RSV or Xpert Xpress Flu/RSV were used as reference test.
bIncluding 10 males that were tested twice.
cNone of the infants with comorbidity were tested twice.
dData available for 125 episodes.
eData available for 160 episodes.
fData available for 99 episodes.
Table 2. Primary Analysis of BinaxNOW RSV Performancea
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Primary analysis (n = 162) 7.6 (5/66) 100 (96/96) 100 (5/5) 61.1 (96/157)
95% CI 3.3–16.5 96.2–100.0 56.6–100.0 54.3–68.4
Abbreviations: CI, confidence interval; n, number of acute respiratory tract infection episodes; NPV, negative predictive value; PPV, positive predictive value.
aData are percentages (proportions) of BinaxNOW RSV test results compared with the reference test.
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on clinical endpoints rather than virological, ensuring a low 
risk of bias. Another strength is that we evaluated the perfor-
mance in different clinical settings with a wide range of disease 
severity. This enabled us to evaluate test performance not only 
in a hospital setting but also in primary care and EDs. Because 
the availability of POCTs is increasing, these tests might also be 
introduced into outpatient settings. Our study added valuable 
information about the sensitivity in different clinical settings, 
which is important to know before implementing POCTs in 
these settings. Finally, we evaluated the test procedure of BN 
thoroughly during the study period to avoid any bias due to in-
correct handling of the tests (see Supplemental Text). We also 
Table 3. BinaxNOW RSV Performance by Different Variables
Variable Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Level of Care Neededa
 Non-MA ARTI (n = 41) 0 (0/5) 100 (36/36) NA (0/0) 87.8 (36/41)
 MA ARTI (n = 83) 9.7 (3/31) 100 (52/52) 100 (3/3) 65.0 (52/80)
 Hospitalized (n = 36) 6.7 (2/30) 100 (6/6) 100 (2/2) 17.6 (6/34)
 PICU (n = 11) 22.2 (2/9) 100 (2/2) 100 (2/2) 22.2 (2/9)
P value .726 NA NA <.005
Age
 ≤60 days (n = 68) 12.5 (3/24) 100 (44/44) 100 (3/3) 67.7 (44/65)
 >60 days (n = 93) 4.8 (2/42) 100 (51/51) 100 (2/2) 56.0 (51/91)
P value .345 NA NA .183
Duration of Symptoms Before Testingb
 ≤5 days (n = 98) 9.8 (5/51) 100 (47/47) 100 (5/5) 50.5 (47/93)
 >5 days (n = 26) 0 (0/8) 100 (18/18) NA (0/0) 69.2 (18/26)
P value >.999 NA NA .119
ReSViNET scorec
 ≤3 (n = 53) 0 (0/17) 100 (36/36) NA (0/0) 67.9 (36/53)
 >3 (n = 46) 12.8 (5/39) 100 (7/7) 100 (5/5) 17.1 (7/41)
P value .309 NA NA <.005
Abbreviations: ARTI, acute respiratory tract infection; MA ARTI, medically attended-ARTI; n, number of ARTI episodes; NA, not applicable; NPV, negative predictive value; PICU, pediatric 
intensive care unit; PPV, positive predictive value; RSV, respiratory syncytial virus.
NOTE: Data are percentages (proportions) of BinaxNOW RSV performance test results compared with the reference test. ReSViNET score was used to evaluate disease severity 
(Supplementary Figure 1).
aData available for 160 episodes.
bData available for 125 episodes.
cData available for 99 episodes.
Table 4. Overview of Characteristics of Published Studies About the Performance of BN Compared With Molecular Tests in Children
Study Age Type of ARTI Reference Test Type of Sample
POC  
Setting  n=
Sensitivity  
(95% CI)
Specificity 
(95% CI)
Present study <1 year (median 
84 days)
Hospitalized, 
(non)-MA ARTI
Alere i,  
Xpert Xpress
NS (flocked  
swabs in 3 mL 
UTM/M4RT)
Yes 162 7.6%  
(3.3–16.5)
100%  
(96.2–100)
Bruning et al [18] <16 years Hospitalized (PICU), 
respiratory illness
RT-PCR NPS, NPW No 66 80%  
(64.3–95.7)
100%  
(NA)
Jung et al [19] <2 years Hospitalized, ALRI RT-PCR NPS in 1.5 mL VTM 
(in-house)
No 91 71.4% (61.4–79.7) NA
Khanom et al [11] <5 years Hospitalized, ARTI RT-PCR NPS in 1 mL VTM 
(in-house)
Yes 159 41.2% (27.9–55.8) 100%  
(95.7–100)
Miernyk et al [7] <3 years (mean 
9.3 months)
Hospitalized, LRTI RT-PCR NPW No 311 72%  
(61–74)
97%  
(94–99)
Mills et al [12] <2 years (mean 
7 months)
ED, respiratory symp-
toms
RT-PCR NPA, NPW Yes 579 83%  
(79–87)
83%  
(78–87)
Papenburg et al [20] <3 years (median 
5.7 months)
Hospitalized, ARTI RT-PCR NPA No 720 80%  
(76–83.5)
96.9%  
(94–98.6)
Pfeil et al [21] <3 years (mean 
7.9 months)
Hospitalized, ARTI RT-PCR NW Yes 242 63%  
(61–76)
100%  
(NA)
Abbreviations: ALRI, acute lower respiratory tract infection; ARTI, acute respiratory tract infection; BN, BinaxNow RSV; CI, confidence interval; ED, emergency department; LRTI, lower res-
piratory tract infection; MA ARTI, medically attended ARTI; NA, not applicable; NPA, nasopharyngeal aspirate; NPS, nasopharyngeal swab; NS, nasal swab; NPW, nasopharyngeal wash; NW, 
nasal wash; PICU, pediatric intensive care unit; POC, point of care; RT-PCR, reverse-transcription polymerase chain reaction; VTM, viral transport media. 
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worked closely with the manufacturer of BN to ensure we used 
the correct procedure.
There are several limitations to our study. First, we did not 
compare viral loads between true-positive and false-negative 
test results. Alere i and Xpert Xpress are qualitative tests. 
The RADT sensitivity depends on viral load [7, 8], whereas 
viral load is positively associated with disease severity [22]. 
In our study, sensitivity in the infants who were admitted to 
the PICU was higher, but this was still only 22% and not sta-
tistically significant higher compared with other clinical set-
tings. Second, in our study, we used the Alere i RSV and Xpert 
Xpress Flu/RSV as reference standards, whereas RT-PCR has 
been used as the gold standard in some other studies [7, 11, 
12, 18–20]. These new molecular assays are reported to have 
a sensitivity (93%–100%) and specificity (96%–100%) compa-
rable with RT-PCR [29–34]. Third, we have not subtyped RSV. 
Respiratory syncytial virus genotype-B infection has been as-
sociated previously with false-negative results of RADT [20]. 
Fourth, we used nasal swabs and not NPS. Viral loads could be 
lower in this anterior nasal region and thus affect sensitivity. 
However, midturbinate flocked swabs have shown to be com-
parable for quantitative detection of RSV in infants [27]. Last, 
we have not analyzed why BN performed suboptimally. It is 
possible that both transport media used in this study, although 
recommended by the manufacturer, had some form of inhibi-
tory effect on the test.
CONCLUSIONS
In conclusion, we have performed the first international pro-
spective population-based study to define the sensitivity of a 
RADT for RSV infection. We showed that BN has low sensi-
tivity in infants with ARTI in different clinical settings when 
collected with a nasal flocked swab in UTM or M4RT transport 
medium. Even in infants with the most severe disease, sensi-
tivity was only 22%. Our study indicates that BN should be used 
and interpreted with caution. More studies are needed to deter-
mine variation in sensitivity with different sampling methods. 
Physicians should consider using more sensitive molecular as-
says for RSV POC testing.
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